INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 84 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $33,364 | +31.6% | 158,500 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $25,360 | -71.2% | 158,500 | 0.0% | 0.00% | -72.7% |
| Q4 2022 | $87,968 | -73.3% | 158,500 | +8.4% | 0.01% | -77.1% |
| Q4 2021 | $329,000 | -34.2% | 146,200 | 0.0% | 0.05% | -42.2% |
| Q3 2021 | $500,000 | +37.4% | 146,200 | +20.0% | 0.08% | +31.7% |
| Q2 2021 | $364,000 | +134.8% | 121,800 | +66.4% | 0.06% | +96.9% |
| Q4 2020 | $155,000 | – | 73,200 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |